Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.


Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and chemoresistant cancers. The serine/threonine kinase Polo-like kinase 1 (PLK1), a key regulator of multiple steps during mitotic progression, is highly expressed in ATC. Here, we used the BI 2536 PLK1 inhibitor on ATC and nontransformed thyroid follicular cell lines. Our data show that ATC… (More)
DOI: 10.1158/0008-5472.CAN-08-1693


5 Figures and Tables